Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2025, Vol. 57 ›› Issue (2): 253-261. doi: 10.19723/j.issn.1671-167X.2025.02.005

Previous Articles     Next Articles

Biological activity and antitumor effect of long-acting recombinant human interleukin-2 drug

Xuejun LIANG, Fengxia ZHANG, Ting JIN, Jingjing ZHU*()   

  1. Novocodex Biopharmaceuticals Company Limited, Shaoxing 312000, Zhejiang, China
  • Received:2024-10-21 Online:2025-04-18 Published:2025-04-12
  • Contact: Jingjing ZHU E-mail:zhujingjing@novocodex.cn

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the biological activity and antitumor effect of pegylated recombinant human interleukin 2 (PEG-rhIL-2) obtained by site-specific conjugation of polyethylene glycol (PEG) with non-natural amino acids, and to explore its antitumor mechanism. Methods: The binding activities of PEG-rhIL-2 at three different sites (T41, Y45, and V91) to human interleukin 2 receptors α (IL-2Rα) and β (IL-2Rβ) and were detected by surface plasmon resonance (SPR) technology. Western blot was used to detect the levels of the Janus kinase-signal transducer and activator of transcription 5 (JAK-STAT5) signaling pathway activated by different doses of rhIL-2 and PEG-rhIL-2 in CTTL-2 and YT cells. Blood was collected after a single administration in mice to detect the drug concentration at different time points and evaluate the pharmacokinetic parameters of Y45-PEG-rhIL-2. Mouse hepatoma cell line Hepa1-6, pancreatic cancer cell line Pan-02, and colon cancer cell line MC-38 were selected. Tumor models were constructed in C57BL/6 mice. Different doses of Y45-PEG-rhIL-2 and excipient control were administrated respectively to evaluate the tumor suppression effect of the drug. In the MC-38 colon cancer model, the tumor suppression effect of Y45-PEG-rhIL-2 combined with anti-programmed death-1 (PD-1) monoclonal antibody was evaluated. Hepa1-6 mouse tumor models were constructed and rhIL-2, Y45-rhIL-2 and Y45-PEG-rhIL-2 were administrated respectively. The proportion of tumor-infiltrating lymphocytes was analyzed by flow cytometry. Results: The SPR detection results showed that the binding activities of PEG-rhIL-2 to IL-2Rα/IL-2Rβ were both reduced. The affinity of Y45-PEG-rhIL-2 to IL-2Rα was reduced to approximately 1/250, and its affinity to IL-2Rβ was reduced to 1/3. Western blot results showed that the activity of Y45-PEG-rhIL-2 in stimulating JAK-STAT5 signaling in CTLL-2 cells expressing heterotrimeric IL-2 receptor complex IL-2Rαβγwas reduced to approximately 1/300, while its activity in YT cells expressing heterodimeric IL-2 receptor complex IL-2Rβγwas reduced to approximately 1/3. The pharmacokinetic evaluation after a single dose in the mice showed that the elimination half-life of Y45-PEG-rhIL-2 was 17.7 h. Y45-PEG-rhIL-2 has pharmacokinetic characteristics superior to those of rhIL-2. Y45-PEG-rhIL-2 showed dose-dependent tumor suppression activity, and the combination of Y45-PEG-rhIL-2 and anti-PD-1 antibody had a better tumor-inhibiting effect than the single use of Y45-PEG-rhIL-2 or anti-PD-1 antibody. Flow cytometry analysis demonstrated that 72 h after the administration of Y45-PEG-rhIL-2, the proportion of tumor-infiltrating cytotoxic T lymphocytes (CD8+T cells) increased by 86.84%. At 120 h after administration, the ratio of CD8+T cells to regulatory T cells (Treg) increased by 75.10%. Conclusion: Y45-PEG-rhIL-2 obtained by site-specific conjugation via non-natural amino acids changed its receptor binding activity and inhibited tumor growth in dose-dependent manner in multiple tumor models by regulating CD8+T cells.

Key words: Recombinant interleukin 2, Non-natural amino acids, Immunotherapy

CLC Number: 

  • R966

Table 1

Binding affinity between various PEG-rhIL-2 and human IL-2 receptors"

Items Equilibrium dissociation constant /(nmol/L)
IL-2Rα Test article/rhIL-2 IL-2Rβ Test article/rhIL-2
rhIL-2 23.0 1.0 355.0 1.0
T41-PEG-rhIL-2 1 130.0 49.1 994.0 2.8
Y45-PEG-rhIL-2 5 650.0 245.7 1 080.0 3.0
V91-PEG-rhIL-2 779.0 33.9 11 400.0 32.1

Figure 1

Activation of CTLL-2 and YT cells by PEG-rhIL-2 at different sites A, CTLL-2 cells; B, YT cells. rhIL-2, recombinant human interleukin 2; PEG-rhIL-2, pegylated recombinant human interleukin 2; EC50, median effect concentration; pSTAT5, phosphorylated signal transducer and activator of transcription 5."

Table 2

Activity parameters of pSTAT5 activation by various PEG-rhIL-2"

Items CTLL-2 cells YT cells
EC50/(μg/L) Test article/rhIL-2 EC50/(μg/L) Test article/rhIL-2
rhIL-2 0.1 1.0 47.6 1.0
T41-PEG-rhIL-2 1.1 8.3 305.1 6.4
Y45-PEG-rhIL-2 44.0 338.0 161.2 3.4
V91-PEG-rhIL-2 0.5 4.1 5 542.0 117.0

Table 3

Pharmacokinetics properties of Y45-PEG-rhIL-2"

Test article AUC0-last/(h × μg/L) Cmax /(μg/L) Tmax/h T1/2/h CL/ [L/(h·kg)]
rhIL-2 2 503.99 6 580.94 0.08 0.80 0.41
Y45-PEG-rhIL-2 161 868.20 26 651.07 0.42 17.70 0.01

Figure 2

Anti-tumor activity of Y45-PEG-rhIL-2 in mouse models A and D, Hepa1-6; B and E, Pan-02; C and F, MC-38. rhIL-2, recombinant human interleukin 2; PEG-rhIL-2, pegylated recombinant human interleukin 2; PD-1, programmed death-1."

Table 4

Tumor growth inhibition of test articles in mouse models"

Dose of drug of model/(mg/kg) TGI/%
Hepa1-6
  Control
    0 -
  Y45-PEG-rhIL-2
    0.1 67.17
    0.3 80.28***
    1.0 105.17***
Pan-02
  Control
    0 -
  Y45-PEG-rhIL-2
    1.0 88.17***
    5.0 106.68***
MC-38
  Control
    0 -
  Y45-PEG-rhIL-2
    1.0 88.11***
    5.0 98.42***
  Anti-PD-1 antibody
    10.0 77.75***
  Y45-PEG-rhIL-2+ anti-PD-1 antibody
    1.0+5.0 98.24***###△△△
    5.0+10.0 98.77***△△△

Figure 3

Body weight changes of mouse models after administration of drugs A, Hepa1-6; B, Pan-02; C, MC-38. PEG-rhIL-2, pegylated recombinant human interleukin 2."

Figure 4

Percentage of tumor infiltrated lymphocytes 72 h and 120 h after Y45-PEG-rhIL-2 administration respectively A, CD45+ in live cells; B, CD4+ in CD45+ cells; C, CD8+ in CD45+ cells; D, Treg in CD45+ cells; E, CD8+/Treg ratio. * P < 0.05; * * P < 0.01; * * * P < 0.001. G1, vehicle control; G2, Y45-PEG-rhIL-2; G3, Y45-rhIL-2; G4, rhIL-2. rhIL-2, recombinant human interleukin 2; PEG-rhIL-2, pegylated recombinant human interleukin 2."

1 Bray F , Ferlay J , Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68 (6): 394- 424.
2 Bray F , Laversanne M , Sung H , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74 (3): 229- 263.
doi: 10.3322/caac.21834
3 Sung H , Ferlay J , Siege RL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71 (3): 209- 249.
doi: 10.3322/caac.21660
4 Raeber ME , Sahin D , Karakus U , et al. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases[J]. EBioMedicine, 2023, 90, 104539.
doi: 10.1016/j.ebiom.2023.104539
5 Ritacco C , Ehx G , Gregoire C , et al. High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2021, 56 (8): 1828- 1841.
doi: 10.1038/s41409-021-01221-0
6 Taniguchi T , Minami Y . The IL-2/IL-2 receptor system: A current overview[J]. Cell, 1993, 73 (1): 5- 8.
doi: 10.1016/0092-8674(93)90152-G
7 Wang X , Lupardus P , Laporte SL , et al. Structural biology of shared cytokine receptors[J]. Annu Rev Immunol, 2009, 27, 29- 60.
doi: 10.1146/annurev.immunol.24.021605.090616
8 Spolski , Li P , Leonard WJ . Biology and regulation of IL-2: From molecular mechanisms to human therapy[J]. Nat Rev Immunol, 2018, 18 (10): 648- 659.
doi: 10.1038/s41577-018-0046-y
9 Boyman O , Sprent J . The role of interleukin-2 during homeostasis and activation of the immune system[J]. Nat Rev Immunol, 2012, 12 (3): 180- 190.
doi: 10.1038/nri3156
10 Fyfe GA , Fisher RI , Rosenberg SA , et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy[J]. J Clin Oncol, 1996, 14 (8): 2410- 2411.
doi: 10.1200/JCO.1996.14.8.2410
11 Rosenberg SA , Yang JC , Topalian SL , et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2[J]. JAMA, 1994, 271 (12): 907- 913.
doi: 10.1001/jama.1994.03510360033032
12 Javia L R , Rosenberg SA . CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens[J]. J Immunother, 2003, 26 (1): 85- 93.
doi: 10.1097/00002371-200301000-00009
13 Yang JC , Sherry RM , Steinberg SM , et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer[J]. J Clin Oncol, 2003, 21 (16): 3127- 3132.
doi: 10.1200/JCO.2003.02.122
14 Rojas G , Relova-Hernandez E , Perez-Riveron A , et al. Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles[J]. Commun Biol, 2023, 6 (1): 828.
doi: 10.1038/s42003-023-05188-0
15 Leonard EK , Tomala J , Gould JR , et al. Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity[J]. JCI Insight, 2024, 9 (18): e173469.
doi: 10.1172/jci.insight.173469
16 Pasut G , Veronese FM . State of the art in PEGylation: the great versatility achieved after forty years of research[J]. J Control Release, 2012, 161 (2): 461- 472.
doi: 10.1016/j.jconrel.2011.10.037
17 Shen BQ , Xu K , Liu L , et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates[J]. Nat Biotechnol, 2012, 30 (2): 184- 189.
doi: 10.1038/nbt.2108
18 Wang L , Brock A , Herberich B , et al. Expanding the genetic code of Escherichia coli[J]. Science, 2001, 292 (5516): 498- 500.
doi: 10.1126/science.1060077
19 Nguyen TTK , Pham KY , Yook S . Engineered therapeutic proteins for sustained-release drug delivery systems[J]. Acta Biomater, 2023, 171, 131- 154.
doi: 10.1016/j.actbio.2023.09.018
20 Charych DH , Hoch U , Langowski JL , et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models[J]. Clin Cancer Res, 2016, 22 (3): 680- 690.
doi: 10.1158/1078-0432.CCR-15-1631
21 Nagaraja-Shastri P , Zhu J , Skidmore L , et al. Nonclinical deve-lopment of next-generation site-specific HER2-targeting antibody-drug conjugate (ARX788) for breast cancer treatment[J]. Mol Cancer Ther, 2020, 19 (9): 1822- 1832.
doi: 10.1158/1535-7163.MCT-19-0692
22 Zhang B , Sun J , Wang Y , et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells[J]. Nat Biomed Eng, 2021, 5 (11): 1288- 1305.
doi: 10.1038/s41551-021-00797-8
23 Sledzinska A , de Mucha MV , Bergerhoff K , et al. Regulatory T cells restrain interleukin-2- and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T Cells[J]. Immunity, 2020, 52 (1): 151. e6- 166. e6.
24 Schmidt D , Endres C , Hoefflin R , et al. Oncogenic calreticulin induces iImmune escape by stimulating TGFbeta expression and regulatory T-cell expansion in the bone marrow microenvironment[J]. Cancer Res, 2024, 84 (18): 2985- 3003.
doi: 10.1158/0008-5472.CAN-23-3553
25 Xie Q , Tang Z , Liang X , et al. An immune-related gene prognostic index for acute myeloid leukemia associated with regulatory T cells infiltration[J]. Hematology, 2022, 27 (1): 1088- 1100.
26 Sharma M , Khong H , Fa'ak F , et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy[J]. Nat Commun, 2020, 11 (1): 661.
doi: 10.1038/s41467-020-14471-1
27 Cheng W , Kang K , Zhao A , et al. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer[J]. J Hematol Oncol, 2024, 17 (1): 54.
28 Liu R , Zeng LW , Li HF , et al. PD-1 signaling negatively regulates the common cytokine receptor gamma chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity[J]. Cell Res, 2023, 33 (12): 923- 939.
[1] Zichen PAN, Kai CHEN, Yukun HOU, Bohan YANG, Jixin ZHANG, Yongsu MA, Xiaodong TIAN, Yinmo YANG. Research progress in clinical pathology and molecular mechanisms of pancreatic adenosquamous carcinoma [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 431-435.
[2] Hao FU, Luyan SHEN, Bingyang HUANG, Shaohua MA. Clinical strategies for perioperative management of esophageal squamous cell carcinoma in the immunotherapy era [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 266-271.
[3] Zhemin LI, Jiafu JI, Guoxin LI, Ziyu LI, Zhaode BU, Xiangyu GAO, Di DONG, Lei TANG, Xiaofang XING, Shuqin JIA, Ting GUO, Lianhai ZHANG, Fei SHAN, Xin JI, Anqiang WANG. Development and dissemination of precision medicine approaches in gastric cancer management [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 864-867.
[4] Jiajun LIU, Guokang LIU, Yuhu ZHU. Immune-related severe pneumonia: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 932-937.
[5] LIU Jing-wei, LU Xu, YANG Zhao-min, DENG Li-juan, YANG Lin. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 840-846.
[6] YE Hai-yun, XU Qing-quan, HUANG Xiao-bo, MA Kai, WANG Xiao-feng. Tuberculous prostatic abscess following intravesical bacillus Calmette-Guérin immunotherapy: a case report [J]. Journal of Peking University(Health Sciences), 2015, 47(6): 1039-1041.
[7] XIAO Zong-Yu, CHEN Xiao-Juan, YANG Yi, XU Ru-Xiang. Experimental study of dendritic cells transfected with cancer stem like cells RNA against 9L brain tumors [J]. Journal of Peking University(Health Sciences), 2015, 47(4): 661-666.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd